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Abstract 
 Toll-like receptors (TLRs) are a specific class of cell membrane spanning proteins that 
recognize and bind foreign microbes.  Over time, these receptors have evolved to recognize well-
conserved features commonly expressed by foreign pathogens including: flagellin proteins, 
lipopolysaccharides (LPS), lipoproteins, and even unmethylated CpG islands found within 
bacterial and viral DNA.  Traditionally, non-covalent interactions between these microbes and 
the TLR invoke a signaling cascade within the cell to ultimately elicit an inflammatory response 
through the recruitment of cytokines and chemokines.   
 
Figure 1.  Extracellular TLR pathway summary.  Ligand binding at the cell surface induces the 
dimerization of the TLR1/2 hereodimer, recruiting adaptor protein complexes to the inner cell 
membrane.  Through a series of cell signaling phosphorylation events, the key transcription 
factor NF-kB is activated and subsequently translocated into the cell nucleus.  Once in the 
nucleus, NF-kB begins transcription of inflammatory related genes required for immune 
response propagation at the cellular and molecular level. 
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The exact TLR signaling mechanism is quite similar to that of receptor tyrosine kinases, in which 
a specific ligand binds and facilitates a cell-specific response through the heterodimerization of 
the TLR.  Specifically the interaction and dimerization of TLR 1 and 2 induces the expression of 
genes involved with inflammation and innate immunity.  Although in vivo TLRs are typically 
activated solely by microbial ligands, recent literature and discoveries have demonstrated 
synthetic small-molecule compounds are similarly capable of eliciting a powerful physiological 
response in vitro.  Investigations into these synthetic agonists have given greater insight into 
how/why these receptors govern such a dramatic change within the cell.  The specific role of this 
project has sought to investigate and explore various TLR 1/2 agonist derivatives building off of 
previous research to ultimately synthesize and test in vitro small molecule agonists capable of 
regulating the TLR complex at the molecular level. 
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Introduction 
General Information regarding Toll-like Receptors and the Innate Immune System 
 More specifically, Toll-Like receptors are type 1 membranous glycoproteins, which are 
characterized by their cytoplasmic Toll/interleukin-1 receptor homology signaling domain 
comprising 19-25 tandem leucine-rich repeats motifs (Kanzler H et al. 2007) See Figure 2.   
 
 
Figure 2.  Crystal Structure of the human TLR 1&2 heterodimer complex with triacyl 
lipopeptide Pam3CSK4, a known TLR1/2 agonist bound within the hydrophobic pocket between 
the two receptors.  The unique horseshoe structure of the TLR 1/2 complex allows the receptor 
to extend relatively far beyond the cell surface to facilitate the recognition of pathogens within 
the immediate environment. 
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The receptor homology helps to accentuate the close relationship regarding the vital role of TLRs 
in the immune system.  The conserved horseshoe structure among TLRs allows for the 
extracellular portion of the receptor to extend relatively far beyond the surface of the cell, to 
further facilitate the recognition of pathogenic species in the immediate extracellular 
environment.  Toll-like receptors are highly conserved throughout vertebrates, humans express 
10 TLR receptors (TLR 1-10), and 12 homologous TLRs are expressed within the mouse model.  
As a result, mouse cell lines are commonly utilized in a laboratory setting to assess the 
potential/preliminary efficacy of various TLR agonists in vitro. 
 The specific conserved molecular sequences TLRs recognize derived from foreign 
microbes are commonly referred to as PAMPs, Pathogen Associated Molecular Patterns 
(Bhardwaj N et al. 2011).  It is important to note that the PAMP associated with the dimerization 
of the TLR 1 and 2 complex are commonly triacyl lipopeptides; commonly expressed by gram-
positive bacteria (Takeda K, Akira S 2005).  Once a foreign pathogen protein binds to a TLR, an 
immune response will consequentially propagate.  Several pathway-specific adaptor proteins are 
recruited to the inner cell membrane.  Downstream activation ultimately triggers 
proinflammatory cytokines (TNF-α and IL-1β for example) and chemokines to be produced via 
MyD88 adaptor recruitment and subsequent downstream phosphorylation events leading to the 
eventual activation of the NF-kB transcription factor.  The overall process constitutes a finely 
tuned molecular defense mechanism to remove the pathogen from the host (So E et al. 2010).   
Because of their selectivity and defensive roles within the body, TLRs are very sensitive 
to mutations.  Over time, these mutations can result in autoimmune disease, multiple forms of 
cancer, and chronic inflammation.  The cells that line the mucosal and epithelial tracts of the 
body contain high numbers of TLRs that are constantly exposed to a variety of foreign 
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pathogens.  Additionally, these TLR expressing cells have high cell-division rates, contributing 
to a higher potential for mutation accumulation relative to a quiescent cell.  Mutations in the 
genes coding for TLR 1&2 expression directly impinge the ability for the receptor to recognize 
PAMPs, causing an altered responsiveness to these bacterial pathogens (Mangesh B et al. 2009).  
It is important to note that a mutation in a specific TLR may subsequently cause the receptor to 
be constitutively activated or repressed; both scenarios are equally detrimental to the organism.  
Several forms of cancer are directly associated with a TLR mutation, causing the receptor 
complex to be hypo suppressed. The ultimate goal of a TLR agonist is to help regulate the 
inflammation response at the cell surface level by developing a small molecule agonist that 
preferentially binds the TLR protein at the cell surface membrane.  Cancer propagation is likely 
associated with tumor cells escaping the surveillance of the TLR, most likely due to a non-
functional receptor (Huang B et al. 2005).  Although, the exact molecular and cellular 
mechanisms are not completely understood, the mutations leading to cancer predominantly alter 
the expression levels of the TLR indicating a potential resistance to conventional cancer 
treatment (So E et al. 2010).  By developing a small molecule agonist of the TLR1&2 
heterodimer, a normal biological level of receptor signaling can potentially be achieved for many 
of these patients suffering from TLR mutations. 
Additionally, many patients suffering from chronic inflammation may have a hyperactive 
(rather than suppressed or defective) form of the gene encoding the TLR protein, which results in 
failure to properly restore signaling to a normal, healthy biological level.  Recent literature 
suggests that chronic inflammation and even autoimmune disease may arise from inappropriate 
response of the receptor due to a genetic mutation within the receptor, or inappropriate quantity 
of ligand (excess of local PAMPs) (Ospelt C et al. 2009).  For these patients, symptoms such as: 
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prolonged joint soreness, swelling and stiffness commonly occur as a result of failure to properly 
clear the immune response from the infection locus.  In this scenario the nature of a small 
molecule agonist would help restore receptor signal by constitutively binding the receptor 
preferentially over an excess of surrounding PAMPs. 
In order to fully understand the dynamic sequence of events following Toll-like Receptor 
binding, it is essential to introduce the innate immune system.  TLRs play a crucial role in 
initiating and enabling the bridge between innate and adaptive immune systems.  The innate 
immune response, or more commonly referred to as the non-specific immune response involves 
the sequence of events prior to the activation of lymphocytes.  A proper analogy equates the 
innate immune response as the “first responder” at the cellular level where Toll-Like receptors 
actually facilitate the communication between the innate and adaptive immune system.  Through 
the induction of a signaling cascade from the cell surface, the cell is able to activate specific 
transcription factors responsible for transcribing genes required for activation and recruitment of 
the lymphocytes necessary to mediate inflammation and remedy infection.  Specifically, it is the 
localized response from foreign infection through the TLR pathway that initiates rapid 
recruitment of inflammatory cells to the site of infection, activating the induction of an 
accumulation of antimicrobial functions (Hayashi F et al. 2003).  Objectively, the innate immune 
response converts a relatively short-lived physiological response into a long-lasting biological 
defense arsenal.  Figure 3 visually summarizes the dynamic interplay between the innate and 
adaptive immune systems. 
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Figure 3.  Critical involvement of TLR signaling in immune response propagation.  
Following pathogen binding at the cell surface TLR, a series of downstream signaling events 
activate key transcription factors involved with immune response propagation.  Specifically, 
NF-kB begins transcribing a multitude of interleukins (responsible for lymphocyte 
growth/differentiation) and TNF-α (responsible for activating macrophage cells).  
Additional gene products provide costimulatory signals required for naïve Tcell 
recruitment and subsequent lymphocyte activation.  These events constitute the bridge 
between innate and adaptive immunity at the cellular level. 
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Integral Role of Specific Transcription Factors and Cytokines 
Ligand binding at the cell surface of the toll-like receptor represents only the first step 
toward the eventual initiation of the early immune response within the cell.  The transcription 
factors and cytokines downstream of the receptor really begin to orchestrate the sequence of 
events following receptor binding, at the molecular level.  The downstream cytosolic 
transcription factor, NF-kB plays a critical role in regulating the innate immune response 
following infection.  NF-kB is an abbreviation for nuclear factor kappa-light-chain-enhancer of 
activated B cells, which interestingly, kappa light 
chains are major components of immunoglobulin 
complexes.  NF-kB is found in almost all animal cell 
types (Gilmore T 2006).  Additionally, improper NF-
kB regulation is largely observed in many cancers 
and chronically active in many inflammatory 
diseases (Monaco C et al. 2004).  For this reason 
NF-kB represents one of the most largely researched 
transcription factors.  
 Prior to receptor binding, NF-kB remains 
sequestered in the cytosol by an inhibitory protein 
complex, IkBa.  This inhibitory complex is important because it allows the transcription factor to 
quickly become activated following infection.  Once the inhibitor is degraded, NF-kB is quickly 
imported into the nucleus to begin immediate transcription of inflammatory related genes, 
without itself having to be transcribed and translated first.  This mechanism of inhibiting an 
inhibitor regarding the NF-kB complex additionally highlights the evolutionary efficiency of the 
Figure 4: NF-kB Structure with DNA 
bound in the center region.  This 
structure facilitates the dynamic role 
of this transcription factor as a key 
regulator of inflammatory genes 
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steps involved with such an important cellular pathway.  Directly upstream of the NF-kB/IkBa 
complex is the IkB (IKK) kinase, responsible for phosporylating the inhibitory domain and 
subsequent release of NF-kB to then enter the cell nucleus.  Of the many downstream products 
NF-kB regulates, some most important downstream products are TNF-α, and inducible Nitric 
oxide synthase (iNOS); these two proteins are beneficial not only for the cell, but for scientists as 
well.  By experimentally assaying for the presence of these proteins (or their products) it is 
possible to begin quantifying agonist efficacy and develop the small molecule agonist.  The exact 
mechanisms and procedures following these assays will be described in full detail in the 
experimental section.   
 
 
 
 
 
 
Another vital downstream component triggered by NF-kB production is the activation of 
inducible Nitric oxide synthase (iNOS) (Figure 5).  Nitric oxide synthases are a family of 
enzymes that catalyze the production of nitric oxide from arginine.  The inducible isoform iNOS 
produces large amounts of NO as an evolutionary defense mechanism, and is synthesized by 
Figure 5: Nitric Oxide production following TLR activation.  NF-kB produces iNOS 
via TLR signaling in response to pathogen presentation outside the cell.  Nitric oxide 
(NO) is produced by iNOS as an evolutionary defense mechanism.  The exact role of 
NO is to regulate a variety of physiological functions such as vasodialation, 
peristalsis and insulin secretion.  Under normal biological conditions, NO will 
quickly oxidize to nitrite.  Experimentally assaying for the presence of nitrite, and 
thus NO, helped to develop the TLR1/2 agonist. 
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many cell types (Stuehr D 2009).  Thus, NO production is very sensitive to cellular cytokine 
levels, which mentioned earlier, are regulated via the TLR pathway.  Nitric oxide is primarily a 
modulation molecule, which helps to balance vital physiological functions including insulin 
secretion, peristalsis, and vasodilation.  The production of nitric oxide is extremely beneficial for 
quantifying TLR agonist efficacy, because nitric oxide can be detected using a micro plate reader 
at a specific wavelength (450nm), which then subsequently allows for the determination of 
agonist strength depending on the concentration of nitric oxide present (typically within the 
nano-molar range).   
 Finally, the third most relevant downstream signaling component of the NF-kB pathway 
is the activation of tumor necrosis factor alpha (TNF-α).  This cytokine is primarily responsible 
for systemic inflammation and stimulation of the acute phase reaction, essentially a positive 
feedback mechanism at the molecular level.  The production of TNF-α along with other 
cytokines stimulates the production of more cytokines throughout more distal locations within 
the body.  TNF-α is primarily produced by activated macrophages, but can also be produced by 
CD4+ expressing lymphocytes and even neurons (Swardfager W et al. 2010).  At the cellular 
level, TNF- α is capable of regulating apoptosis and inhibition of viral replication and 
tumorigenesis.  Binding of TNF-α to the TNF receptor at the cell surface initiates recruitment of 
adaptor proteins to ultimately induce activation of caspase 8 and/or the JNK transcription factor, 
both proteins are associated with the orchestration of apoptosis.  Finally, the TNF receptor can 
activate IKK, which then proceeds to activate NF-kB as mentioned previously.   
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Small Molecule Agonist Development of the TLR 1/2 Heterodimer 
 Recent scientific endeavors regarding the construction of TLR-based therapeutics have 
demonstrated a strong potential as promising candidates for many patients with chronic 
inflammation and chronic pain-associated symptoms.  Currently, there are two main approaches 
utilized that allow scientists to design compounds and target a cell surface receptor: synthetic 
ligands, and small molecule agonists (Kanzler H et al. 2007).  The former involves developing a 
synthetic version of a natural pre-existing TLR ligand, screened to optimize pharmacological 
properties such as half-life, toxicity, and various pharmacodynamics (breakdown, absorption and 
systemic distribution).  The latter method involves synthesizing small molecule organic 
compounds designed to mimic the natural ligand in terms of binding strength and physiological 
response, although the actually physical structure of the synthetically derived agonist may be 
entirely different.  Once a potential candidate is identified, the most common application of the 
TLR agonist at the clinical level is to serve as a vaccine adjuvant designed to enhance the 
recipient’s adaptive immune response.  Typically concentration values for such an adjuvant are 
generally on the pico to nano molar scale.  The purpose of the adjuvant is to introduce the 
agonist at the lowest possible dose, but to still elicit a physiological response.  For this reason, 
toxicity screens are absolutely vital when assessing the efficacy of a potential target.  While this 
may seem simple in principle, there are many challenges, however, scientists face due to the 
sheer complexity involved in targeting/studying cellular signaling pathways.  TLR agonists are 
pro-inflammatory, and the extent of the inflammation involved is difficult to modulate at a 
molecular level.  Furthermore, prior to entering clinical trials the compound dosage must 
minimize unwanted inflammation and possible toxicity.  This task may seem daunting initially to 
scientists; however, recent studies have illustrated the necessary homeostasis of TLR signaling 
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within specific mucosal tracts are subject to relatively routine bacterial/pathogen exposure i.e. 
epithelia cells of the intestinal tract.  Cells within these tracts of the body are constantly exposed 
to TLR ligands from bacteria occupying or passing through the immediate environment.  
However, these cells manage to avoid chronic inflammation that these ligand concentrations 
would seemingly elicit.  These recent studies suggest that a non-zero basal level of TLR 
signaling is actually required throughout the intestinal tracts.  And furthermore, adequate basal 
TLR signaling levels are absolutely necessary for maintaining the integrity of intestinal 
epithelium and protection from inflammation-mediated damage (Lee J et al. 2006).   
 
 
Experimental Methods 
Cell Culture 
Throughout the course of the experiment, cell culture was used daily to prepare cell 
samples for compound testing.  A total of two different cell lines were used throughout the 
project duration: Raw 264.7 cells, and HEK-Blue-TLR2 cells.  Raw cells are type of mouse 
macrophage cell line and are quite reliable as they express 10 homologous TLR proteins found in 
humans.  HEK-Blue-TLR2 cells are a human embryonic kidney cell line.  Cells were stored at 
370C and split every 3-4 days depending on the approximate doubling time of the specific cell 
line.  Raw cells were cultured in RPMI media with 10% FBS and 1% Pen/Strep; HEK-Blue-
TLR2 were cultured in DMEM media with 10% FBS and 1% Pen/Strep.  Prior to compound 
testing, cells were plated in 96-well plates at 80,000 cells/well for Raw cells and 40,000 
cells/well for HEK-Blue-TLR2 cells.  Following 24 hours of incubation in the 96-well plates, the 
cells were ready for compound addition.   
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Compound Preparation 
 Synthesized compounds were obtained and diluted to 20mM in dimethyl sulfoxide 
(DMSO).  DMSO is a polar aprotic solvent commonly used in a laboratory setting to dissolve 
both polar and nonpolar organic compounds.  The dose dependence of the compound was 
calculated to maximize in vitro response.  Commonly, new compound dose dependence ranged 
from 0-10µM or 0-5µM to obtain a preliminary benchmark for the behavior of the compound 
when cells were present.  Ideally, a Gaussian distribution would be obtained that would then 
allow future experiments to maximize agonist efficacy by “zooming in” using smaller 
concentration increments to obtain the most accurate data and gain preliminary understanding 
regarding compound behavior.  Compounds were prepared from the 20mM stock solution into a 
96-well plate.  RPMI was used as dilution media for the Nitric oxide assay and Opti-Mem media 
was used for the SEAP assay preparation.  Once the compound was added, the cells incubated 
for 24 hours prior to testing.   
 
 
 
 
Assessing Cell Viability: MTT assay and Trypan Blue 
 When testing small molecule agonists in cell culture it was necessary to periodically 
assess cell viability in the presence of these compounds.  Assessing cellular toxicity is a 
necessary prerequisite to assess the efficacy of a new compound.  Ultimately, MTT and Trypan 
blue helped to eliminate any potential ambiguity as to whether a compound was simply less 
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effective at a given concentration, or cells were simply dying as a result of compound toxicity.  
Throughout this experiment the two main procedures used for assesing cell viability were trypan 
blue and the MTT Assay.  Trypan blue is an organic dye added directly to a cell sample and 
visualized using light microscopy.  The trypan blue dye traverses the cell membrane of dead cells 
only.  When visualizing under a microscope it is fairly easy to discern dead cells from live cells.  
Dead cells and live cells were tabulated and recorded.  A simple ratio was then taken to obtain 
the viable percentage of cells for a particular compound.  Another method used to determine 
viable cell counts was an MTT assay, which proved very useful throughout the experiment.  
MTT, similar to trypan blue, is a water-soluble dye that when taken up by a viable cell is reduced 
to insoluble formazan, yielding a dark purple color.  Following 4 hours of incubation cell 
viability of the sample could be quantified using a microplate absorbance reader at 570nm.  This 
assay essentially measures cellular metabolic activity of NADH-dependent oxidoreductase 
efficiency found in the mitochondria (Berridge M et al. 2005).  By using a positive and negative 
control, the results could be normalized and as a result, the percent cell viability could be 
determined.   
 
 
Nitric Oxide assay 
 The Nitric oxide assay served as a powerful analytic tool to measure the effect of agonist 
concentration on subsequent TLR signaling.  The downstream activation of iNOS by NF-kB 
signaling allows for the production of Nitric oxide (NO).  The concentration of NO was then 
experimentally detected by adding the molecule 2,3-diaminonapthalene, diluted in 0.62M HCl.  
In the presence of NO, 2,3-diaminonapthalene will fluoresce at 430nm, as detected via micro 
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plate reader.  Prior to reading, the plate was shaken for 15 minutes after 5µL of 3M NaOH was 
then added to quench any remaining HCl in the reaction media.  The output of reflective 
absorbance values were converted to a nano molar NO concentration using a conserved value. 
 
 
 
SEAP Assay 
 Secreted alkaline phosphatase (SEAP) is a reporter gene used for the assay of promoter 
activity and inflammatory response levels.   By detecting secreted alkaline phosphatase activity, 
the SEAP assay links the NF-kB response elements to SEAP gene allowing quantitative 
measurement of NF-kB activity.  Thus measured SEAP activity is directly associated with 
cellular inflammation response from compound addition.  The presence of SEAP catalyzes the 
hydrolysis of pNitrophenyl phosphate (PNPP) and produces a visibly yellow color that can be 
read at 405 nm using a microplate reader.  One of the advantages of the SEAP assay is that the 
reagent is taken up locally, so cell lysis is not required for enzymatic detection 
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Pam 3CSK4 Compound 
 Pam3-Cys-Ser-Lys4 is a small protein activator of the TLR1&2 heterodimer.  Throughout 
the duration of the experiment, Pam3CSK4 was frequently utilized as a positive control to 
generate a strong nitric oxide signal in cell culture.  Pam3CSK4 would help confirm competency 
of cells in addition to serving as an efficient benchmark to quantify agonist efficacy.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Pam3CSK4 : A triacyl lipoprotein agonist of the TLR1/2 complex used as a probe to study 
the TLR signaling pathway 
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Results 
 
  
Figure 6.  Activation of TLR signaling via NO production with increasing concentration of 
T12_9.  The above experiment was conducted using Raw cells that express all homologous 
TLRs found in humans.  Nitric oxide assay was used to assess the levels of Nitric oxide 
production, which are reflective of TLR signaling levels following compound addition.  The 
triacly lipopeptide Pam3CSK4 (a known TLR1/2 heterodimer agonist) was added as a 
positive control at 100ng/mL to ensure the competency of the cells.  The potential agonist 
compound T12_9 was added to the cells in a dose dependent manner (0-10µM).  These data 
show that following compound T12_9 addition, a significant increase in NO signaling occurs 
within the 0-5uM ranges.  Compound T12_9 is likely a TLR agonist and additional data 
aims to optimize the effective dose of T12_9 to maximize TLR signaling. 
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Figure 7.  TLR activation in the presence of potential agonist compounds T12_9, T12_14 
and T12_17.  Nitric oxide assay was performed using Raw cells.  Nitric oxide (NO) levels 
were measured to assess the level of TLR signaling following addition of various potential 
TLR1/2 agonist compounds.  The triacyl lipopeptide, Pam3CSK4 was added (blue bar), as a 
positive control, at 200ng/mL to ensure competency of the cells.  The compounds T12_14 
and T12_17 show approximately zero increased TLR activation when compound 
concentration was increased.  Compound T12_9, from concentrations 1-5µM shows a 
considerable increase in TLR signaling via NO production.  When combined with the 
previous figure, these data display the potential of T12_9 as small molecule agonist of the 
TLR1/2 complex. 
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Figure 8.  Trypan Blue toxicity test from concentrations (0-100µM) for compound T12_9.  
Toxicity screens were necessary to ascertain whether a potential agonist compound was 
toxic at higher concentrations.  Trypan blue, an organic dye, was added locally to the cell 
sample (using Raw cells).  The dye is able to traverse the cell membrane of dead cells only.  
When using light microscopy it is easy to discern live versus dead cells.  A simple ratio was 
then taken, and results were plotted with increasing concentration of T12_9.  The Trypan 
blue toxicity assay indicates that cellular toxicity of T12_9 will unlikely be problematic in 
subsequent experiments. 
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Figure 9.  MTT toxicity test from concentrations (0-50µM) for compound T12_9.  
MTT, an organic dye is similar to Trypan Blue.  When added to Raw cells, MTT 
will cross the cell membrane where it is subsequently oxidized, yielding a dark 
purple color.  The opacity of the sample was read using a microplate reader at 
450nm.  When compared with a blank, a viable cell count could be obtained from 
the normalized data.  In the experiment above, cell viability percentages were 
obtained for potential TLR 1/2 agonist compound T12_9 from concentrations 0-
50µM.  These data complement figure 8 and together, indicate that a 
concentration increase of the T12_9 compound has no effect on cell viability. 
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Figure 10.  Optimizing TLR activation showing peak NO signal at 1µM concentration.  
Using Raw cells, it was necessary repeat the dose dependence experiment for compound 
T12_9 several times to optimize scientific understanding regarding the biological properties 
of compound behavior.  Utilizing Nitric oxide assay, the results indicate the peak nitric 
oxide signal for compound T12_9 occurs at 1µM.  The resulting TLR activation induced by 
compound T12_9 indicate that this compound is a likely TLR activator.  Follow-up 
experiments are necessary to determine the potential specificity of the small molecule 
compound, T12_9. 
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Figure 11.  SEAP Assay indicating TLR2 activation with increasing concentration of 
T12_9; EC50%~50nM.  The SEAP assay uses a pNitrophenol phosphate dye that is 
hydrolyzed by secreted embryonic alkaline phosphatase, (transcribed by the NF-kB 
transcription factor) which produces a bright yellow color within the sample media.  
The sample can be read using a microplate reader at 405nm.  The level of 
luminescence is reflective of SEAP presence, and thus NF-kB activity, and ultimately 
TLR activation.  An increase in luminescence following compound addition is 
indicative of TLR signaling.  This experiment was conducted using Hek-Blue-TLR2 
cells that exclusively express the hTLR2 protein.  Thus, any signal detected is 
directly reflective of TLR2 activation alone.  This experiment was conducted to 
determine whether the potential agonist compound T12_9 is TLR specific for the 
desired TLR1/2 heterodimer.  These results indicate that an increase in T12_9 
concentration causes an increase in SEAP luminescence, which is reflective of the 
amount of TLR signaling.  Because luminescence increases following compound 
addition, small molecule agonist T12_9 selectively targets and activates the TLR1/2 
heterodimer complex.   
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Figure 12.  Subsequent TLR activation following increasing concentration of TLR4 
inhibitor: Tak242.  The previous figure indicates the selectivity of the T12_9 agonist 
compounds for TLR1/2.  It was also necessary to experimentally verify (using Raw cells 
expressing all TLRs) that the small agonist compound T12_9 is non-specific for other 
TLR proteins expressed on the cell surface membrane.  By increasing the dose of the 
TLR4 Tak242 antagonist from 0-100nM, the experiment shows that Tak242 has no 
influence on TLR signaling when T12_9 is present at 1µM.  Thus compound T12_9 is 
not competing with the Tak242 antagonist for TLR binding sites and further verifies the 
selective nature of compound T12_9 as a small molecule agonist of the TLR1/2 complex.   
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Discussion 
  The compound T12_9 experimentally displayed the greatest TLR signaling activation as 
indicative of Nitric oxide detection.  Utilizing the Nitric oxide assay, figure 7 shows other 
potential small molecule agonist candidates of the TLR1/2 heterodimer.  It is quite clear, 
however, that T12_9 substantially increases TLR activation within the 1-5µM ranges.  The Nitric 
oxide assay in figure 6 shows that the activation trend for T12_9 follows a normal distribution, 
with TLR activation diminishing at higher concentrations.  However, in order to determine 
whether T12_9 was potentially toxic, or simply not as efficient at inducing TLR activation at 
higher concentrations, it was necessary to periodically test the cellular viability of T12_9 in Raw 
cells.  The Trypan Blue toxicity assay in figure 8 indicates that cells remained viable following 
compound T12_9 concentrations up to 100µM.  In addition, the MTT assay in figure 9 reflects 
similarly that cellular toxicity is unlikely a reason for decreased TLR signaling at greater 
compound concentrations.  Together, both the MTT assay and Trypan blue assay indicate that 
cellular toxicity of the small molecule agonist compound T12_9 will unlikely be problematic in 
following experiments.  The nitric oxide assay in figure 10 sought to achieve a more 
comprehensive biological understanding of T12_9 behavior through experimental triplication.  
At 1µM T12_9, signaling via the TLR pathway produces approximately 120-300 nM of nitric 
oxide, which corresponds to significant amount of inflammatory response at the cellular level.  
At this point it was known that compound T12_9 was indeed a TLR activator, but following 
experiments needed to confirm the specificity of the compound for TLR1/2.  The SEAP assay in 
figure 11 verifies that the T12_9 small molecule agonist does indeed selectively target the 
TLR1/2 heterodimer complex.  Because the Hek-Blue-TLR2 cells solely express the TLR2 
protein, any signal detection can be directly attributed to TLR2 activation.  The detected SEAP 
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luminescence was proportional to the concentration of T12_9 present.  This illustrates that small 
molecule agonist, T12_9, is specific for TLR2 and thus the TLR1/2 heterodimer.  It was also 
necessary to experimentally confirm that the agonist T12_9 is non-specific for other TLR 
proteins expressed on the cell surface membrane.  The nitric oxide assay in figure 12 indicates 
that TLR signaling continues even when Tak242, a known TLR4 inhibitor is present.  Thus 
TLR4 agonist is not capable of altering TLR signaling due to T12_9 presence.  Because these 
two compounds target different TLR proteins, Tak242 and T12_9 are not competing for TLR 
binding sites at the cell surface membrane.  When combined these experiments illustrate that 
small molecule compound T12_9 is TLR1/2 selective and an activator of TLR signaling in vitro.  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